Results 91 to 100 of about 761 (100)

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

Lancet, The, 2023
BACKGROUND: Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable activity on S1P2,3, is in development for the treatment of immune-mediated ...
Filip Baert, Martina Goetsch, Timothy Ritter   +2 more
exaly   +2 more sources

Design and synthesis of etrasimod derivatives as potent antibacterial agents against Gram-positive bacteria

European Journal of Medicinal Chemistry
The emergence of multidrug-resistant bacteria along with a declining pipeline of clinically useful antibiotics has led to the urgent need for the development of more effective antibacterial agents.
Jayendra Z Patel, Leena Hanski, Jari Tapani Yli-Kauhaluoma   +2 more
exaly   +2 more sources

Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials

Journal of Crohn's and Colitis
Background and aims: Etrasimod is an oral, once daily, selective sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis [UC]. This subgroup analysis evaluated the efficacy and safety of
Silvio Danese, Severine Vermeire, Michael Chiorean   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Etrasimod for the Treatment of Ulcerative Colitis

Immunotherapy, 2023
Pauline Wils, Laurent Peyrin-Biroulet
exaly  

Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis

Annals of Pharmacotherapy
David Choi, Shubha Bhat
exaly  

Therapeutic Potential of Etrasimod in the Management of Moderately-to-Severely Active Ulcerative Colitis: Evidence to Date

Clinical and Experimental Gastroenterology
Christopher Fan
exaly  

Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme

Journal of Crohn's and Colitis
Britta Siegmund, Abhishek Bhattacharjee, Aoibhinn McDonnell   +2 more
exaly  

Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme

Journal of Crohn's and Colitis
Silvio Danese, Severine Vermeire, Walter Reinisch   +2 more
exaly  

Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study

Clinical Pharmacology in Drug Development
exaly  

Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults

Clinical Pharmacology in Drug Development
exaly